论文部分内容阅读
为了解儿童青少年使用5-羟色胺(5-HT)再摄取抑制剂(SSRIs)与有害事件的关联,对已公开发表的临床随机对照试验报告及流行病学资料进行分析。尽管有研究报告揭示SSRIs与日益增多的有害事件有关,但已知的临床研究结果并不能提供足够的证据,证明两者之间存在关联。对严重抑郁障碍,最佳治疗方案应为氟西汀与认知行为治疗相结合;SSRIs不应作为治疗轻、中度抑郁症的首选药物而应作为二线治疗药物。对SSRIs与有害事件的相关性有必要进一步做出及时评估,为其临床安全应用提供可靠依据。
To understand the association of serotonin (5-HT) reuptake inhibitors (SSRIs) with adverse events in children and adolescents, published reports of clinical randomized controlled trials and epidemiological data were analyzed. Although studies have reported that SSRIs are associated with an increasing number of adverse events, the results of known clinical studies do not provide sufficient evidence of a link between the two. For severe depression, the best treatment should be fluoxetine and cognitive behavioral therapy combined; SSRIs should not be used as the treatment of mild to moderate depression drugs should be used as second-line treatment. It is necessary to make further assessment on the relativity between SSRIs and harmful events so as to provide a reliable basis for its clinical safety application.